SCHEMBL284607

SCHEMBL284607

CCCCCCCCC=CCCCCCCCCCCCCCCCCC=CCCCCCCCC(N)=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 1.00
SOAT1 P35610 2/20 1.00
CYP1A2 P05177 2/20 1.00
CYP2C19 P33261 2/20 1.00
KMT2A Q03164 2/20 1.00
MEN1 O00255 1/20 1.00
TP53 P04637 1/20 1.00
CYP3A4 P08684 1/20 1.00
KDM4E B2RXH2 2/20 0.89
CNR1 P21554 1/20 0.78
TERT O14746 3/20 0.70
PTPN1 P18031 3/20 0.70
PPARG P37231 3/20 0.70
PPARD Q03181 3/20 0.70
PPARA Q07869 3/20 0.70
MAPT P10636 2/20 0.70
BLM P54132 2/20 0.70
HSD17B10 Q99714 2/20 0.70
FABP4 P15090 2/20 0.70
GMNN O75496 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oleamide SCHEMBL19814150 1.00 FAAH (1.00) FAAHSOAT1CYP1A2CYP2C19KMT2A
SCHEMBL10445439 1.00 FAAH (1.00) FAAHSOAT1CYP1A2CYP2C19KMT2A
SCHEMBL21983255 1.00 FAAH (1.00) FAAHSOAT1CYP1A2CYP2C19KMT2A
SCHEMBL23528231 1.00 FAAH (1.00) FAAHSOAT1CYP1A2CYP2C19KMT2A
SCHEMBL10445419 1.00 FAAH (1.00) FAAHSOAT1CYP1A2CYP2C19KMT2A
SCHEMBL24340776 1.00 FAAH (1.00) FAAHSOAT1CYP1A2CYP2C19KMT2A
SCHEMBL21501560 1.00 FAAH (1.00) FAAHSOAT1CYP1A2CYP2C19KMT2A
SCHEMBL21654359 1.00 FAAH (1.00) FAAHSOAT1CYP1A2CYP2C19KMT2A
SCHEMBL22419041 1.00 FAAH (1.00) FAAHSOAT1CYP1A2CYP2C19KMT2A
Oleamide SCHEMBL6668979 1.00 FAAH (1.00) FAAHSOAT1CYP1A2CYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2428566-B1 GENE TRANSFER AGENT COMPOSITION CONTAINING POLYAMIDOAMINE DENDRON PUBLIC UNIVERSITY CORP OSAKA PREFECTURE UNIVERSITY (JP) 2015-08-26 EP disclosed
WO-2013172358-A1 FUNCTIONAL COMPOUND, MOLECULAR ASSEMBLY CONTAINING FUNCTIONAL COMPOUND, COMPOSITION CONTAINING MOLECULAR ASSEMBLY, KIT, AND USE OF MOLECULAR ASSEMBLY, COMPOSITION OR KIT 公立大学法人大阪府立大学 (JP) 2013-11-21 WO disclosed
US-8557875-B2 Gene transfer agent composition containing polyamidoamine dendron PUBLIC UNIVERSITY CORPORATION OSAKA PREFECTURE UNIVERSITY (JP) 2013-10-15 US disclosed
EP-2428566-A1 GENE TRANSFER AGENT COMPOSITION CONTAINING POLYAMIDOAMINE DENDRON Public University Corporation Osaka Prefecture University (JP) 2012-03-14 EP disclosed
US-20120053233-A1 GENE TRANSFER AGENT COMPOSITION CONTAINING POLYAMIDOAMINE DENDRON PUBLIC UNIVERSITY CORPORATION OSAKA PREFECTURE UNIVERSITY (JP) 2012-03-01 US disclosed
EP-0783296-B1 NOVEL COMPOSITIONS FOR THE INTRODUCTION OF POLYANIONIC MATERIALS INTO CELLS INEX PHARMACEUTICALS CORP (CA) 2002-06-26 EP disclosed
EP-1179340-A2 Compositions for the introduction of polyanionic materials into cells INEX Pharmaceutical Corp. (CA) 2002-02-13 EP disclosed
US-6268534-B1 CONTACTING OLEYL BROMIDE WITH OLEYLAMINE UNDER CONDITIONS SUITABLE FOR THE FORMATION OF N,N-DIOLEYLAMINE; METHYLATION OF N,N-DIOLEYLAMINE UNDER CONDITIONS SUITABLE FOR FORMATION OF N,N-DIOLEYL-N,N-DIMETHYLAMMONIUM CHLORIDE RIBOZYME PHARMACEUTICALS, INC. 2001-07-31 US disclosed
US-5785992-A LIPOSOMES AND CATIONIC COMPOUNDS INEX PHARMACEUTICALS CORP. (CA) 1998-07-28 US disclosed
EP-0783296-A1 NOVEL COMPOSITIONS FOR THE INTRODUCTION OF POLYANIONIC MATERIALS INTO CELLS INEX Pharmaceutical Corp. (CA) 1997-07-16 EP disclosed
WO-1996010390-A1 NOVEL COMPOSITIONS FOR THE INTRODUCTION OF POLYANIONIC MATERIALS INTO CELLS INEX PHARMACEUTICALS CORP. (CA) 1996-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053233-A1 GENE TRANSFER AGENT COMPOSITION CONTAINING POLYAMIDOAMINE DENDRON CXCR4, KPNA2, MCTS1 FAAH 2620/4885SOAT1 2601/4885CYP1A2 1876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.